News Articles and Montana BioScience Alliance Newsletters
Device developed by Missoula company Gaize (gaize.ai) could help to keep people safe at work and on the road.
2M Beta is a 12-week program delivering the foundational and modern skills required to transform influential ideas into thriving businesses. With access to more professional expertise, more state-of-the-art technology and more community resources, C2M Beta was founded with the mission to connect local entrepreneurs to more!
A message from Board President Cynthia Tsai
SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, announce an agreement in principle to create a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development. This collaboration leverages Inimmune’s world-class expertise in adjuvant formulation and immunotherapeutics and SPI Pharma’s extensive manufacturing and global commercial capabilities.
NIAID scientists and colleagues are investigating a potential treatment strategy against Lyme disease that would directly suppress Borrelia burgdorferi, the bacterium that causes the disease. If successful, their idea could reduce or end aggressive broad-spectrum antibiotic treatments that can be drawn-out and destroy the body’s helpful bacteria.
The biennial report provides a national snapshot of the most pressing current and anticipated talent needs of the nation’s dynamic life science industry. This year’s report distills a set of key themes sourced from 185 executive interviews and nearly 700 survey responses from companies in eighteen states and Puerto Rico, as well as an assessment of nearly 2.8M job postings from life science companies over the last four years.
Drug makers have been racing at a breakneck pace to develop respiratory syncytial virus (RSV) vaccines this year. On May 3, the U.S. Food and Drug Administration (FDA) announced it has approved Arexvy, the first-ever RSV vaccine for individuals 60 and over.
Information on Small Business Funding Webinar, National Small Business Week, America’s SEED Fund Week — and more
SBIR and STTR grant funding opportunities offer small business entrepreneurs a chance to obtain non-dilutive funding for early-stage research and development. Applications are accepted three times a year. The next deadline is April 5. Omnibus Solicitations. Researcher-initiated ideas are proposed via the SBIR and STTR Omnibus grant solicitations. These FOAs do not specify a topic, though they link to identified topics of interest for each participating awarding component. Most small business applications to NIH are submitted to the Omnibus solicitations. Specific Funding […]
FDA advisers endorsed the safety and efficacy of GSK’s respiratory syncytial virus (RSV) vaccine in older adults, setting up a final mad dash with Pfizer as both companies eye the regulatory finish line with their promising new vaccines.
View the September 2024 Newsletter now!
View the Summer 2024 Newsletter now!